These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11330837)

  • 1. Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.
    Ouyang X; Gulliford T; Zhang H; Smith G; Huang G; Epstein RJ
    Mol Cell Biochem; 2001 Feb; 218(1-2):47-54. PubMed ID: 11330837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH.
    Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
    Cell Signal; 2012 Nov; 24(11):1981-8. PubMed ID: 22800866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensification of growth factor receptor signalling by phorbol treatment of ligand-primed cells implies a dimer-stabilizing effect of protein kinase C-dependent juxtamembrane domain phosphorylation.
    Gulliford T; Ouyang X; Epstein RJ
    Cell Signal; 1999 Apr; 11(4):245-52. PubMed ID: 10372802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The duration of phorbol-inducible ErbB2 tyrosine dephosphorylation parallels that of receptor endocytosis rather than threonine-686 phosphorylation: implications for the physiological role of protein kinase C in growth factor receptor signalling.
    Ouyang X; Gulliford T; Epstein RJ
    Carcinogenesis; 1998 Nov; 19(11):2013-9. PubMed ID: 9855018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2.
    Gulliford TJ; Huang GC; Ouyang X; Epstein RJ
    Oncogene; 1997 Oct; 15(18):2219-23. PubMed ID: 9393980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.
    Yuan T; Wang Y; Zhao ZJ; Gu H
    J Biol Chem; 2010 May; 285(20):14861-14870. PubMed ID: 20335174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization.
    Hughes JB; Berger C; Rødland MS; Hasmann M; Stang E; Madshus IH
    Mol Cancer Ther; 2009 Jul; 8(7):1885-92. PubMed ID: 19584234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction.
    Huang GC; Ouyang X; Epstein RJ
    Biochem J; 1998 Apr; 331 ( Pt 1)(Pt 1):113-9. PubMed ID: 9512468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms.
    Johannessen LE; Haugen KE; østvold AC; Stang E; Madshus IH
    Biochem J; 2001 May; 356(Pt 1):87-96. PubMed ID: 11336639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the domain in ErbB2 that restricts ligand-induced degradation.
    Shen F; Lin Q; Childress C; Yang W
    Cell Signal; 2008 Apr; 20(4):779-86. PubMed ID: 18255265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
    Lu Y; Zi X; Zhao Y; Pollak M
    Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
    Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
    Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.
    Zaman GJ; Vink PM; van den Doelen AA; Veeneman GH; Theunissen HJ
    Biochem Pharmacol; 1999 Jan; 57(1):57-64. PubMed ID: 9920285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site.
    Jansen SM; Sleumer LS; Damen E; Meijer IM; van Zoelen EJ; van Leeuwen JE
    Cell Signal; 2009 May; 21(5):810-8. PubMed ID: 19263517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.
    Wosikowski K; Schuurhuis D; Johnson K; Paull KD; Myers TG; Weinstein JN; Bates SE
    J Natl Cancer Inst; 1997 Oct; 89(20):1505-15. PubMed ID: 9337347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.